Publication

(18)F-DCFPyL PET/CT in the Detection of Prostate Cancer at 60 and 120 Minutes: Detection Rate, Image Quality, Activity Kinetics, and Biodistribution

Wondergem, M., van der Zant, F. M., Knol, R. J. J., Lazarenko, S. V., Pruim, J. & de Jong, I. J., 1-Nov-2017, In : Journal of Nuclear Medicine. 58, 11, p. 1797-1804 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • (18)F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes

    Final publisher's version, 1 MB, PDF document

DOI

There is increasing interest in PET/CT with prostate-specific membrane antigen (PSMA) tracers for imaging of prostate cancer because of the higher detection rates of prostate cancer lesions than with PET/CT with choline. For Ga-68-PSMA-11 tracers, late imaging at 180 min after injection instead of imaging at 45-60 min after injection improves the detection of prostate cancer lesions. For (18)F-DCFPyL, improved detection rates have recently been reported in a small pilot study. In this study, we report the effects of PET/CT imaging at 120 min after injection of (18)F-DCFPyL in comparison to images acquired at 60 min after injection in a larger clinical cohort of 66 consecutive patients with histopathologically proven prostate cancer. 

Methods: Images were acquired 60 and 120 min after injection of (18)F-DCFPyL. We report the positive lesions specified for anatomic locations (prostate, seminal vesicles, local lymph nodes, distant lymph nodes, bone, and others) at both time points by visual analysis, the image quality at both time points, and a semiquantitative analysis of the tracer activity in both prostate cancer lesions as well as normal tissues at both time points. 

Results: Our data showed a significantly increasing uptake of (18)F-DCFPyL between 60 and 120 min after injection in 203 lesions characteristic for prostate cancer (median, 10.78 vs. 12.86, P <0.001, Wilcoxon signed-rank test). By visual analysis, 38.5% of all patients showed more lesions using images at 120 min after injection than using images at 60 min after injection, and in 9.2% a change in TNM staging was found. All lesions seen on images 60 min after injection were also visible on images 120 min after injection. A significantly better mean signal-tonoise ratio of 11.93 was found for images acquired 120 min after injection (P <0.001, paired t test; signal-to-noise ratio at 60 min after injection, 11.15). 

Conclusion: (18)F-DCFPyL PET/CT images at 120 min after injection yield a higher detection rate of prostate cancer characteristic lesions than images at 60 min after injection. Further studies are needed to elucidate the best imaging time point for (18)F-DCFPyL.

Original languageEnglish
Pages (from-to)1797-1804
Number of pages8
JournalJournal of Nuclear Medicine
Volume58
Issue number11
Publication statusPublished - 1-Nov-2017

    Keywords

  • F-18-DCFPyL, PET/CT, prostate cancer, urology, image acquisition, GA-68-LABELED PSMA LIGAND, GA-68-PSMA-11 HBED-CC, MEMBRANE ANTIGEN, RADIATION-DOSIMETRY, INTEGRATED PET/CT, DIAGNOSIS, RECURRENCE, EXPRESSION, ANTIBODIES, UTILITY

ID: 41687794